MCID: PRT096
MIFTS: 49

Peritoneal Mesothelioma

Categories: Cancer diseases, Gastrointestinal diseases, Rare diseases

Aliases & Classifications for Peritoneal Mesothelioma

MalaCards integrated aliases for Peritoneal Mesothelioma:

Name: Peritoneal Mesothelioma 12 6 15 17 70
Malignant Mesothelioma of Peritoneum 12 70
Advanced Malignant Mesothelioma of Peritoneum 12
Advanced Malignant Peritoneal Mesothelioma 12
Advanced Peritoneal Malignant Mesothelioma 70

Classifications:



External Ids:

Disease Ontology 12 DOID:1788
NCIt 50 C8704 C9350
SNOMED-CT 67 187806007
ICD10 32 C45.1
UMLS 70 C0346109 C0854886 C1377610

Summaries for Peritoneal Mesothelioma

Disease Ontology : 12 A peritoneum cancer that develops from cells of the mesothelium and is located in the peritoneum.

MalaCards based summary : Peritoneal Mesothelioma, also known as malignant mesothelioma of peritoneum, is related to malignant peritoneal mesothelioma and benign peritoneal mesothelioma, and has symptoms including abdominal pain An important gene associated with Peritoneal Mesothelioma is LATS2 (Large Tumor Suppressor Kinase 2), and among its related pathways/superpathways are Gastric cancer and Glioma. The drugs Doxorubicin and Ranpirnase have been mentioned in the context of this disorder. Affiliated tissues include peritoneum, breast and lung, and related phenotypes are Decreased viability and Decreased viability

Wikipedia : 73 Peritoneal mesothelioma is the name given to the cancer that attacks the lining of the abdomen. This... more...

Related Diseases for Peritoneal Mesothelioma

Diseases in the Peritoneal Mesothelioma family:

Benign Peritoneal Mesothelioma Malignant Peritoneal Mesothelioma

Diseases related to Peritoneal Mesothelioma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 446)
# Related Disease Score Top Affiliating Genes
1 malignant peritoneal mesothelioma 32.6 NF2 MUC1 EGFR CDKN2A BAP1
2 benign peritoneal mesothelioma 32.2 WT1 MUC1 CEACAM5 CALB2
3 benign mesothelioma 31.8 WT1 THBD NF2 CEACAM5 CDKN2A CALB2
4 rare tumor 31.5 NF2 LATS2
5 asbestosis 30.9 WT1 THBD MUC1 CALB2
6 pseudomyxoma peritonei 30.8 MUC16 MUC1 CEACAM5
7 tuberculous peritonitis 30.5 MUC16 CEACAM5
8 cholecystitis 30.4 MUC1 EGFR CDKN2A
9 pleural disease 30.4 NF2 EGFR CEACAM5 CALB2 BAP1
10 primary peritoneal carcinoma 30.4 PGR MUC16 EGFR
11 endometriosis 30.3 PGR MUC16 ESR1 CALB2
12 malignant epithelial mesothelioma 30.2 THBD CEACAM5 CALB2
13 neurilemmoma 30.2 NF2 MUC1 CALB2
14 malignant biphasic mesothelioma 30.2 WT1 THBD CALB2
15 adenomatoid tumor 30.1 WT1 THBD CALB2
16 intravenous leiomyomatosis 30.1 PGR ESR1
17 pericardial mesothelioma 30.1 MUC16 MUC1 CALB2
18 papillary adenocarcinoma 30.0 PGR MUC16 MUC1 CEACAM5
19 lung squamous cell carcinoma 30.0 EGFR CDKN2A CD274 ALK
20 papillary carcinoma 29.9 PGR MUC1 MET ESR1 CALB2
21 mesothelioma, malignant 29.9 WT1 THBD NF2 MUC16 MUC1 MET
22 leiomyomatosis 29.9 WT1 PGR ESR1 CALB2
23 cystadenoma 29.9 PGR MUC16 MUC1 CEACAM5 CALB2
24 ovarian serous cystadenocarcinoma 29.8 PGR MUC16 CEACAM5
25 dedifferentiated liposarcoma 29.8 MUC1 MET CDKN2A
26 peritoneum cancer 29.8 WT1 NF2 EGFR CEACAM5 CDKN2A CALB2
27 adenocarcinoma 29.8 MUC1 MET EGFR CEACAM5 CDKN2A ALK
28 colon adenocarcinoma 29.7 ESR1 EGFR CEACAM5 CD274 CALB2
29 ewing sarcoma 29.7 WT1 EGFR CDKN2A BAP1 ALK
30 sarcomatoid mesothelioma 29.6 WT1 THBD MUC1 CDKN2A CALB2 BAP1
31 wilms tumor 1 29.6 WT1 PGR MUC1 ESR1 CALB2
32 kidney cancer 29.3 WT1 MET EGFR CDKN2A CD274
33 renal cell carcinoma, nonpapillary 29.1 XIAP WT1 MUC1 MET EGFR CD274
34 mucinous adenocarcinoma 29.1 PGR MUC16 MUC1 ESR1 EGFR CEACAM5
35 lung cancer susceptibility 3 29.1 MUC16 MUC1 MET EGFR CEACAM5 CDKN2A
36 malignant peripheral nerve sheath tumor 29.0 WT1 NF2 MUC1 MET EGFR CDKN2A
37 malignant pleural mesothelioma 28.9 XIAP WT1 THBD NF2 MUC1 MET
38 melanoma, uveal 28.6 NF2 MET LATS1 HMGB1 EGFR CDKN2A
39 esophageal cancer 28.6 XIAP MUC1 EGFR CEACAM5 CDKN2A CD274
40 ovarian cancer 28.3 XIAP WT1 PGR MUC16 MUC1 MET
41 benign multicystic peritoneal mesothelioma 11.7
42 peritoneal cystic mesothelioma 11.2
43 asbestos intoxication 10.5
44 peritonitis 10.4
45 spindle cell thymoma 10.4 MUC1 CALB2
46 intestinal obstruction 10.4
47 thrombocytosis 10.4
48 esophagus verrucous carcinoma 10.4 EGFR CDKN2A
49 liver fibroma 10.4 THBD CALB2
50 pancreatic foamy gland adenocarcinoma 10.4 MUC1 CEACAM5

Graphical network of the top 20 diseases related to Peritoneal Mesothelioma:



Diseases related to Peritoneal Mesothelioma

Symptoms & Phenotypes for Peritoneal Mesothelioma

UMLS symptoms related to Peritoneal Mesothelioma:


abdominal pain

GenomeRNAi Phenotypes related to Peritoneal Mesothelioma according to GeneCards Suite gene sharing:

26 (show all 12)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-1 9.88 EGFR
2 Decreased viability GR00055-A-2 9.88 EGFR
3 Decreased viability GR00221-A-1 9.88 ALK CDKN2A EGFR ESR1 LATS2
4 Decreased viability GR00221-A-2 9.88 ESR1 LATS2
5 Decreased viability GR00221-A-3 9.88 CDKN2A
6 Decreased viability GR00221-A-4 9.88 ALK CDKN2A EGFR ESR1 LATS2
7 Decreased viability GR00249-S 9.88 ALK
8 Decreased viability GR00386-A-1 9.88 ESR1
9 Decreased viability GR00402-S-2 9.88 ESR1
10 Decreased cell migration GR00055-A-1 9.55 ALK LATS1 MET NF2
11 Decreased cell migration GR00055-A-3 9.55 EGFR
12 Decreased sensitivity to paclitaxel GR00112-A-0 8.96 LATS1 WT1

MGI Mouse Phenotypes related to Peritoneal Mesothelioma:

46 (show all 15)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.34 ALK BAP1 CD274 CDKN2A EGFR ESR1
2 cellular MP:0005384 10.31 BAP1 CD274 CDKN2A EGFR ESR1 LATS1
3 cardiovascular system MP:0005385 10.29 BAP1 CDKN2A EGFR ESR1 LATS1 LATS2
4 endocrine/exocrine gland MP:0005379 10.29 ALK BAP1 CDKN2A EGFR ESR1 LATS1
5 immune system MP:0005387 10.26 BAP1 CD274 CDKN2A EGFR ESR1 LATS1
6 mortality/aging MP:0010768 10.25 ALK BAP1 CD274 CDKN2A EGFR ESR1
7 embryo MP:0005380 10.22 BAP1 CDKN2A EGFR ESR1 LATS2 MET
8 integument MP:0010771 10.2 ALK BAP1 CD274 CDKN2A EGFR ESR1
9 liver/biliary system MP:0005370 10.09 CDKN2A EGFR ESR1 LATS1 LATS2 MET
10 muscle MP:0005369 10.02 BAP1 CDKN2A EGFR ESR1 LATS2 MET
11 neoplasm MP:0002006 10.02 ALK BAP1 CDKN2A EGFR ESR1 LATS1
12 no phenotypic analysis MP:0003012 9.96 BAP1 CD274 CDKN2A EGFR ESR1 LATS1
13 normal MP:0002873 9.9 ALK CALB2 EGFR ESR1 LATS1 LATS2
14 reproductive system MP:0005389 9.7 ALK BAP1 CDKN2A EGFR ESR1 LATS1
15 respiratory system MP:0005388 9.28 ALK BAP1 CDKN2A EGFR ESR1 MET

Drugs & Therapeutics for Peritoneal Mesothelioma

Drugs for Peritoneal Mesothelioma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 35)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Doxorubicin Approved, Investigational Phase 3 23214-92-8 31703
2
Ranpirnase Investigational Phase 3 196488-72-9
3
Liposomal doxorubicin Phase 3 31703
4 Antibiotics, Antitubercular Phase 3
5 Anti-Bacterial Agents Phase 3
6
Bortezomib Approved, Investigational Phase 2 179324-69-7 387447 93860
7
Oxaliplatin Approved, Investigational Phase 2 61825-94-3 5310940 9887054 6857599 43805
8
Gemcitabine Approved Phase 2 95058-81-4 60750
9
Cisplatin Approved Phase 2 15663-27-1 84093 441203 2767
10
Pemetrexed Approved, Investigational Phase 2 150399-23-8, 137281-23-3 446556 60843
11
Levoleucovorin Approved, Investigational Phase 2 68538-85-2 149436
12
Talazoparib Approved, Investigational Phase 2 1207456-01-6 135565082
13
Folic acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
14 Alkylating Agents Phase 2
15 Interferon-gamma Phase 2
16 Mitomycins Phase 2
17 interferons Phase 2
18
Erlotinib Hydrochloride Phase 2 183319-69-9 176871
19 Protein Kinase Inhibitors Phase 2
20 Immunosuppressive Agents Phase 2
21 Immunologic Factors Phase 2
22 Antiviral Agents Phase 2
23 Anti-Infective Agents Phase 2
24 Antimetabolites Phase 2
25 Folic Acid Antagonists Phase 2
26 Vitamin B9 Phase 2
27 Folate Phase 2
28 Vitamin B Complex Phase 2
29 Poly(ADP-ribose) Polymerase Inhibitors Phase 2
30
Cyclophosphamide Approved, Investigational Phase 1 50-18-0, 6055-19-2 2907
31
Sirolimus Approved, Investigational Phase 1 53123-88-9 5284616 6436030
32 Antirheumatic Agents Phase 1
33 Immunotoxins Phase 1
34
Pancrelipase Approved, Investigational 53608-75-6
35 pancreatin

Interventional clinical trials:

(show all 15)
# Name Status NCT ID Phase Drugs
1 ONCONASE Plus Doxorubicin Versus Doxorubicin For Patients With Malignant Pleural or Peritoneal Mesothelioma Who Have Had No More Than One Prior Chemotherapy Regimen Unknown status NCT00003034 Phase 3 doxorubicin hydrochloride;ranpirnase
2 A Two Stage, Open Label, Phase II Study of VELCADE Plus ELOXATIN in Previously Treated Patients With Malignant Pleural or Peritoneal Mesothelioma Unknown status NCT00996385 Phase 2 Velcade (bortezomib) plus Eloxatin (oxaliplatin)
3 Phase II Trial Of Combined Resection, Intraperitoneal Chemotherapy, And Whole Abdominal Radiation For Treatment Of Peritoneal Mesothelioma Unknown status NCT00024271 Phase 2 cisplatin;doxorubicin hydrochloride;gemcitabine hydrochloride;mitomycin C
4 Phase II Study of Erlotinib for Patients With Malignant Peritoneal Mesothelioma (MPeM) Exhibiting EGFR Mutations Completed NCT01592383 Phase 2 erlotinib hydrochloride
5 Oxaliplatin (Eloxatin®) Plus Gemcitabine as First or Second-line Chemotherapy for Patients With Malignant Pleural or Peritoneal Mesothelioma: A Phase II Clinical Trial Completed NCT00859469 Phase 2 Oxaliplatin;Gemcitabine
6 ALIMTA Plus Gemcitabine as Front-Line Chemotherapy for Patients With Malignant Pleural or Peritoneal Mesothelioma: A Phase II Clinical Trial Completed NCT00061477 Phase 2 Pemetrexed;Gemcitabine
7 Phase II Multicenter Randomized Trial Evaluating the Association of PIPAC and Systemic Chemotherapy Versus Systemic Chemotherapy Alone as 1st-line Treatment of Malignant Peritoneal Mesothelioma Recruiting NCT03875144 Phase 2 Cisplatin;Pemetrexed
8 A Three-Cohort Phase II Trial to Assess the Efficacy of a Maintenance Treatment With TALAzoparib Following First Line Platinum-based Chemotherapy in Pleural or Malignant Peritoneal MESOthelioma Patients Not yet recruiting NCT04462809 Phase 2 Talazoparib
9 A Phase 1 Study of Intraperitoneal MCY-M11 Therapy for Women With Platinum Resistant High Grade Serous Adenocarcinoma of the Ovary, Primary Peritoneum, or Fallopian Tube, or Subjects With Peritoneal Mesothelioma With Recurrence After Prior Chemotherapy Active, not recruiting NCT03608618 Phase 1 Cyclophosphamide
10 A Phase I Study of the Mesothelin-Targeted Immunotoxin LMB-100 in Combination With SEL-110 in Subjects With Malignant Pleural or Peritoneal Mesothelioma Terminated NCT03436732 Phase 1 LMB-100;SEL-110
11 French National Registry of Rare Peritoneal Surface Malignancies (RENAPE Registry) Unknown status NCT02834169
12 Genomic Analysis of Peritoneal Mesothelioma by CGH Arrays Completed NCT02834234
13 Survival of Peritoneal Mesothelioma After Cytoreductive Surgery and Hyperthermic Intra-peritoneal Chemotherapy (HIPEC) Completed NCT01812148
14 Tissue Procurement for Gastric Cancer, Gastrointestinal Stromal Tumors (GIST), Esophageal Cancer, Pancreas Cancer, Hepatocellular Cancer, Biliary Cancer, Neuroendocrine, Peritoneal Mesothelioma, Anal Cancer and Colorectal Cancer in Patients Undergoing Surgery or Biopsy Recruiting NCT01416714
15 Magnetic Resonance Imaging for Detection of Peritoneal Mesothelioma Recruiting NCT03867578

Search NIH Clinical Center for Peritoneal Mesothelioma

Genetic Tests for Peritoneal Mesothelioma

Anatomical Context for Peritoneal Mesothelioma

The Foundational Model of Anatomy Ontology organs/tissues related to Peritoneal Mesothelioma:

19
Peritoneum

MalaCards organs/tissues related to Peritoneal Mesothelioma:

40
Breast, Lung, Ovary, Thyroid, Liver, Kidney, Colon

Publications for Peritoneal Mesothelioma

Articles related to Peritoneal Mesothelioma:

(show top 50) (show all 1367)
# Title Authors PMID Year
1
STRN-ALK rearranged pediatric malignant peritoneal mesothelioma - Functional testing of 527 cancer drugs in patient-derived cancer cells. 61
33530027 2021
2
Efficacy of second-line treatment and prognostic factors in patients with advanced malignant peritoneal mesothelioma: a retrospective study. 61
33743636 2021
3
Comment on "Heterogeneity in PD-L1 expression in malignant peritoneal mesothelioma with systemic or intraperitoneal chemotherapy". 61
33339893 2021
4
Outcomes of multicystic peritoneal mesothelioma treatment with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. 61
33688945 2021
5
Response to Comment on "Heterogeneity in PD-L1 expression in malignant peritoneal mesothelioma with systemic or intraperitoneal chemotherapy". 61
33318658 2021
6
Complete pathological response after ceritinib for anaplastic lymphoma kinase-rearranged epithelioid peritoneal mesothelioma. 61
33740310 2021
7
Phase 1 cohort expansion study of LY3023414, a dual PI3K/mTOR inhibitor, in patients with advanced mesothelioma. 61
33660194 2021
8
Intraperitoneal Chemotherapy for Peritoneal Metastases: Technical Innovations, Preclinical and Clinical Advances and Future Perspectives. 61
33804167 2021
9
A Novel Malignant Peritoneal Mesothelioma with STRN Exon 2 and ALK Exon 20: A Case Report and Literature Review. 61
33555117 2021
10
Re-evaluating the pathogenicity of the c.783+2T>C BAP1 germline variant. 61
33600035 2021
11
Malignant Peritoneal Mesothelioma Arising in Young Adults With Long-standing Indwelling Intra-abdominal Shunt Catheters. 61
32826527 2021
12
Malignant Peritoneal Mesothelioma Associated With Endometriosis: A Clinicopathologic Study of 15 Cases. 61
33577225 2021
13
Nivolumab activity in advanced refractory malignant peritoneal mesothelioma. 61
33358840 2021
14
Pediatric Malignant Peritoneal Mesothelioma With Meningeal Metastasis. 61
33633025 2021
15
Heterogeneity in PD-L1 expression in malignant peritoneal mesothelioma with systemic or intraperitoneal chemotherapy. 61
33100328 2021
16
Synchronous breast carcinoma and peritoneal mesothelioma. 61
33619768 2021
17
Malignant peritoneal mesothelioma: prognostic significance of clinical and pathologic parameters and validation of a nuclear-grading system in a multi-institutional series of 225 cases. 61
33060816 2021
18
Prolonged survival with systemic chemotherapy in an advanced malignant mesothelioma: A case report. 61
33613924 2021
19
Comments on a recent case-control study of malignant mesothelioma of the pericardium and the tunica vaginalis testis. 61
32626907 2021
20
Benign multicystic peritoneal mesothelioma (BMPM) presenting with ambiguous symptoms: A rare case report. 61
33391761 2021
21
The Delphi and GRADE methodology used in the PSOGI 2018 consensus statement on Pseudomyxoma Peritonei and Peritoneal Mesothelioma. 61
30954350 2021
22
Establishment and histopathological study of patient-derived xenograft models and primary cell lines of epithelioid malignant peritoneal mesothelioma. 61
33473097 2021
23
Peritoneal mesothelioma: PSOGI/EURACAN clinical practice guidelines for diagnosis, treatment and follow-up. 61
32209311 2021
24
Peritoneal Mesothelioma in a Free-Ranging American Black Bear (Ursus americanus). 61
33635984 2021
25
The Role of Hyperthermic Intraperitoneal Chemotherapy for Non-colorectal Peritoneal Surface Malignancies. 61
32808135 2021
26
Unresectable peritoneal metastasis treated by pressurized intraperitoneal aerosol chemotherapy (PIPAC) leading to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. 61
31253545 2021
27
Phase II Trial of Adjuvant Dendritic Cell Vaccine in Combination with Celecoxib, Interferon-α, and Rintatolimod in Patients Undergoing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Metastases. 61
33400000 2021
28
Malignant peritoneal mesothelioma presenting as a splenic mass. 61
33161309 2020
29
Unusual radiologic presentations of malignant peritoneal mesothelioma. 61
33510855 2020
30
Forecast of Malignant Peritoneal Mesothelioma Mortality in Italy up to 2040. 61
33379304 2020
31
ASO Author Reflections: Improving Outcomes in Diffuse Malignant Peritoneal Mesothelioma: Challenges and Opportunities. 61
32239340 2020
32
CRS/HIPEC with Major Organ Resection in Peritoneal Mesothelioma Does not Impact Major Complications or Overall Survival: A Retrospective Cohort Study of the US HIPEC Collaborative. 61
33073341 2020
33
Parahiatal hernia sac tumor of localized malignant peritoneal mesothelioma. 61
33359504 2020
34
Peritoneal mesothelioma associated with bladder cancer and occupational exposure to asbestos: A case report. 61
33363966 2020
35
Pediatric PK/PD Phase I Trial of Pexidartinib in Relapsed and Refractory Leukemias and Solid Tumors Including Neurofibromatosis Type I-Related Plexiform Neurofibromas. 61
32943455 2020
36
Massive Ascites Secondary to Malignant Peritoneal Mesothelioma. 61
31982608 2020
37
Whole exome sequencing reveals BAP1 somatic abnormalities in mesothelioma in situ. 61
32932212 2020
38
A Case of Localized Malignant Peritoneal Mesothelioma Evaluated by 18F-FDG PET/CT. 61
32604114 2020
39
A case of sarcomatoid malignant peritoneal mesothelioma diagnosed by laparoscopy. 61
33015277 2020
40
Molecular characterization of diffuse malignant peritoneal mesothelioma. 61
32504035 2020
41
Nivolumab for malignant peritoneal mesothelioma. 61
33257382 2020
42
Long-term results of laparoscopic cytoreductive surgery and HIPEC for the curative treatment of low-grade pseudomyxoma peritonei and multicystic mesothelioma. 61
31792692 2020
43
The role of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the treatment of peritoneal carcinomatosis: a systematic review including evidence from Japan. 61
33185798 2020
44
Curcumin Treatment Identifies Therapeutic Targets within Biomarkers of Liver Colonization by Highly Invasive Mesothelioma Cells-Potential Links with Sarcomas. 61
33207594 2020
45
ALK positive malignant peritoneal mesothelioma mimicking inflammatory myofibroblastic tumour: a diagnostic pitfall. 61
32814620 2020
46
Malignant Peritoneal Mesothelioma Presenting with Polymyalgia Rheumatica-like Syndrome. 61
32581164 2020
47
A Case of Localized Malignant Peritoneal Mesothelioma With Lung Cancer Detected by 18F-FDG PET/CT. 61
32558713 2020
48
A Phase II Trial of Alisertib (MLN8237) in Salvage Malignant Mesothelioma. 61
32608142 2020
49
Sarcomatoid malignant peritoneal mesothelioma presenting as a localized mesenteric tumor with no previous asbestos exposure. 61
33149886 2020
50
A comprehensive review of childbearing after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. 61
32653946 2020

Variations for Peritoneal Mesothelioma

ClinVar genetic disease variations for Peritoneal Mesothelioma:

6
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 LATS2 NM_014572.3(LATS2):c.2699_2700insC (p.Val901fs) Insertion Likely pathogenic 619198 rs1565941245 GRCh37: 13:21553902-21553903
GRCh38: 13:20979763-20979764
2 LATS1 NM_004690.4(LATS1):c.2636G>A (p.Trp879Ter) SNV Likely pathogenic 619199 rs1408705745 GRCh37: 6:149997831-149997831
GRCh38: 6:149676695-149676695
3 MECOM NM_004991.4(MECOM):c.262C>T (p.Pro88Ser) SNV Uncertain significance 619200 rs1560202272 GRCh37: 3:169099088-169099088
GRCh38: 3:169381300-169381300

Expression for Peritoneal Mesothelioma

Search GEO for disease gene expression data for Peritoneal Mesothelioma.

Pathways for Peritoneal Mesothelioma

Pathways related to Peritoneal Mesothelioma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.39 PGR MET ESR1 EGFR CDKN2A
2
Show member pathways
12.16 MET ESR1 EGFR CDKN2A ALK
3 12.16 XIAP MET ESR1 EGFR CDKN2A ALK
4 11.25 WT1 ESR1 EGFR
5 10.26 NF2 LATS2 LATS1

GO Terms for Peritoneal Mesothelioma

Cellular components related to Peritoneal Mesothelioma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cell surface GO:0009986 9.1 THBD MET HMGB1 EGFR CEACAM5 CD274

Biological processes related to Peritoneal Mesothelioma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription by RNA polymerase II GO:0045944 9.7 WT1 PGR MET HMGB1 ESR1 EGFR
2 regulation of inflammatory response GO:0050727 9.58 XIAP ESR1 BAP1
3 positive regulation of kinase activity GO:0033674 9.5 MET EGFR ALK
4 phosphorylation GO:0016310 9.43 MET LATS2 LATS1 EGFR CDKN2A ALK
5 intracellular steroid hormone receptor signaling pathway GO:0030518 9.37 PGR ESR1
6 regulation of organ growth GO:0046620 9.26 LATS2 LATS1
7 negative regulation of cyclin-dependent protein serine/threonine kinase activity GO:0045736 8.8 LATS2 LATS1 CDKN2A

Molecular functions related to Peritoneal Mesothelioma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 10.35 XIAP WT1 THBD PGR NF2 MUC16
2 protein kinase activity GO:0004672 9.72 MET LATS2 LATS1 EGFR ALK
3 ATPase binding GO:0051117 9.43 PGR ESR1 EGFR
4 nitric-oxide synthase regulator activity GO:0030235 9.16 ESR1 EGFR
5 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.13 MET EGFR ALK
6 kinase activity GO:0016301 9.1 MET LATS2 LATS1 EGFR CDKN2A ALK

Sources for Peritoneal Mesothelioma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....